Skip to main content
OpenTrials
Completed

NCT Number: NCT04487860

Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

This is a randomized, double blind, placebo-controlled, phase II study. The study will be performed as a multicenter, multinational study.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Sun Pharma Site 19, Ahmedabad, Gujarat, India

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provide written informed consent.
  • Male or female ≥ 18 years of age at time of screening
  • Stable (without new patches ≥ 1 year) or unstable (with new patches for the last 1 year) vitiligo
  • VASI of ≥ 4 at screening and baseline

Exclusion criteria

  • Segmental vitiligo, focal, or mixed Vitiligo
  • Subjects who have high risk of suicidality at the Screening assessment based on Investigator's judgment
  • History of alcohol or drug abuse in the previous 2 years
  • Subjects who were submitted to melanocyte transfer

-

Treatment and study plan

AS012

Drug

oral administration

Placebo

Drug

oral administration

Primary outcomes

  1. Mean Change From Baseline in Vitiligo Area Scoring Index Score

    Time frame: Week 24

    Vitiligo Area Scoring Index score: numeric score that can range from 0 to 100, with higher VASI scores denoting poorer the disease state

Secondary outcomes

  1. Mean Change From Baseline in Vitiligo Extent Score (VES) on Clinical Pictures

    Time frame: Week 24

    The Vitiligo Extent Score (VES) measures the overall vitiligo involvement in the body based on clinical pictures reflecting the natural distribution of the disease across 19 body areas (e.g., face, trunk, arms, legs, hands, axillae, back, gluteal). For each area, one representative image is selected, assigning one of six degrees of involvement (1%, 5%, 10%, 25%, 50%, 75%). The total and final score is the sum of the measurements from all areas, calculated using a conversion table available in the online calculator (www.vitiligo-calculator.com), and expressed as the extension of body surface area affected (0-100). Higher scores indicate worse clinical involvement. The VES change from baseline to Week 24 was assessed for the ITT population.

  2. Mean Change in Vitiligo Impact Patient Scale

    Time frame: Week 24

    Subjects will be asked to complete a questionnaire to assess the burden experienced by individuals affected. For each of the statements in the Vitiligo Impact Patient Scale, 7 responses are suggested: always, very often, often, sometimes, rarely, never and not applicable. The individual answered as spontaneously as possible while thinking about their situation over the last 7 days. Summary scores range from 0 to 100. Higher values indicate a worse clinical condition.

  3. Physician's Global Assessment Scores

    Time frame: Week 52

    Description: The investigator will perform an average assessment of all vitiligo lesions. The following scale will be used for the PGA: Score 0= No involvement, Score 1= Limited, Score 2= moderate, Score 3= Extensive or Score 4= Very extensive. Higher values indicate a worse clinical condition. The static Physician's Global Assessment determines vitiligo extend at a single point in time, without taking the baseline disease condition into consideration, in other words, represents the Proportion of subjects achieving a PGA score of "no involvement" (score 0) or "limited extent" (score 1) with at least 2-point reduction from Baseline Week 52.

  4. Mean Change From Baseline in Dermatology Life Quality Index

    Time frame: Week 52

    The DLQI scores are based on the response from the patient. Each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired OR lower scores indicate better quality of life.

Sponsors and collaborators

Lead sponsor

Ache Laboratorios Farmaceuticos S.A.

Industry

Registry information

Official study title

A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

Important dates

Study start
2021
Primary completion
2022
Study completion
2023
First posted
Jul 27, 2020
Registry last updated
Mar 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.